259 related articles for article (PubMed ID: 15103328)
1. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation.
Fernández CO; Hoyer W; Zweckstetter M; Jares-Erijman EA; Subramaniam V; Griesinger C; Jovin TM
EMBO J; 2004 May; 23(10):2039-46. PubMed ID: 15103328
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
[TBL] [Abstract][Full Text] [Related]
3. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
4. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation.
Binolfi A; Lamberto GR; Duran R; Quintanar L; Bertoncini CW; Souza JM; Cerveñansky C; Zweckstetter M; Griesinger C; Fernández CO
J Am Chem Soc; 2008 Sep; 130(35):11801-12. PubMed ID: 18693689
[TBL] [Abstract][Full Text] [Related]
5. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
J Mol Biol; 2004 Jun; 340(1):127-39. PubMed ID: 15184027
[TBL] [Abstract][Full Text] [Related]
6. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein.
Kaylor J; Bodner N; Edridge S; Yamin G; Hong DP; Fink AL
J Mol Biol; 2005 Oct; 353(2):357-72. PubMed ID: 16171820
[TBL] [Abstract][Full Text] [Related]
7. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
Uversky VN
J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
[TBL] [Abstract][Full Text] [Related]
8. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations.
Dedmon MM; Lindorff-Larsen K; Christodoulou J; Vendruscolo M; Dobson CM
J Am Chem Soc; 2005 Jan; 127(2):476-7. PubMed ID: 15643843
[TBL] [Abstract][Full Text] [Related]
9. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
10. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
Li HT; Du HN; Tang L; Hu J; Hu HY
Biopolymers; 2002 Aug; 64(4):221-6. PubMed ID: 12115139
[TBL] [Abstract][Full Text] [Related]
11. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
12. A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles.
Bisaglia M; Tessari I; Pinato L; Bellanda M; Giraudo S; Fasano M; Bergantino E; Bubacco L; Mammi S
Biochemistry; 2005 Jan; 44(1):329-39. PubMed ID: 15628875
[TBL] [Abstract][Full Text] [Related]
13. Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding.
Yamaguchi Y; Masuda M; Sasakawa H; Nonaka T; Hanashima S; Hisanaga S; Kato K; Hasegawa M
J Mol Biol; 2010 Jan; 395(3):445-56. PubMed ID: 19895818
[TBL] [Abstract][Full Text] [Related]
14. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.
Andringa G; Lam KY; Chegary M; Wang X; Chase TN; Bennett MC
FASEB J; 2004 May; 18(7):932-4. PubMed ID: 15001552
[TBL] [Abstract][Full Text] [Related]
15. Nuclear localization of alpha-synuclein and its interaction with histones.
Goers J; Manning-Bog AB; McCormack AL; Millett IS; Doniach S; Di Monte DA; Uversky VN; Fink AL
Biochemistry; 2003 Jul; 42(28):8465-71. PubMed ID: 12859192
[TBL] [Abstract][Full Text] [Related]
16. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation.
Munishkina LA; Henriques J; Uversky VN; Fink AL
Biochemistry; 2004 Mar; 43(11):3289-300. PubMed ID: 15023080
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of PLD2 inhibition by alpha-synuclein.
Payton JE; Perrin RJ; Woods WS; George JM
J Mol Biol; 2004 Apr; 337(4):1001-9. PubMed ID: 15033366
[TBL] [Abstract][Full Text] [Related]
18. Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro.
Goers J; Uversky VN; Fink AL
Protein Sci; 2003 Apr; 12(4):702-7. PubMed ID: 12649428
[TBL] [Abstract][Full Text] [Related]
19. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
Fujiwara H; Hasegawa M; Dohmae N; Kawashima A; Masliah E; Goldberg MS; Shen J; Takio K; Iwatsubo T
Nat Cell Biol; 2002 Feb; 4(2):160-4. PubMed ID: 11813001
[TBL] [Abstract][Full Text] [Related]
20. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
